Fig. 7
PIP5K1A loss has minimal impact on HRAS-mutant or NRAS-mutant cancer cells. Percent cell viability (mean ± SD, triplicate samples, two experiments, normalized to vector control cells treated with DMSO) of the indicated a HRAS-mutant and b NRAS-mutant human cancer cell lines stably infected with a lentiviral vector encoding Cas9 and no transgene (vector) or one of up to three independent sgRNA targeting PIP5K1A (sgPIP5K1A-1 to -3) after treatment with vehicle (DMSO) or 25 nM of trametinib for 72 h. *p = 0.05, two-way ANOVA test
